Windlas Biotech Q1 FY27 call set for Aug 11, 2026

Overview: what Windlas Biotech announced

Windlas Biotech Limited has scheduled a conference call to discuss its financial results for the quarter ended June 30, 2026 (Q1 FY27). The call is set for August 11, 2026 at 11:30 AM IST, and is intended to give investors and analysts an opportunity to interact with the management team. The company said the discussion will cover operational and financial outcomes for the quarter.

The announcement comes as market participants position for the July-August 2026 results season. In parallel, multiple market-data snapshots in the provided material show the stock trading at different levels, including around ₹882.10 on BSE at 4:01 PM on August 7 and a stated current share price of ₹882.85.

Conference call: time, purpose, and management participation

According to the details shared, the call will include participation from key executives, including Hitesh Windlass and Komal Gupta. The stated objective is to discuss the quarter ended June 30, 2026 and answer questions from investors and analysts.

The invite is also available on the company’s website (www.windlas.com). Investor contacts mentioned for further information are Ankit Jain and Manveer Sharma at Stellar IR.

Key details investors will track

The company is part of the pharmaceuticals and life sciences space, with operations spanning development, manufacturing, and marketing of generic and branded pharmaceutical products. Another section of the provided material describes Windlas Biotech as an Indian pharmaceutical company founded in 2001, specialising in the development and manufacturing of generic drug formulations.

Windlas Biotech’s model includes contract development and manufacturing services (CDMO) for other pharmaceutical companies, alongside marketing its own generic medicines. The business is presented across three verticals: CDMO, Domestic Trade Generics and Institutional, and Exports.

Conference call details table

Price and valuation snapshots cited in the material

The inputs include several reference points for Windlas Biotech’s stock and valuation. One segment lists the share price as ₹812, with market cap at ₹1.6K crore and P/E ratio at 24.6. Another section frames the stock “trading at ₹851” with market capitalisation of ₹1,773 crore and a price-to-earnings multiple of 26.7.

Separately, a BSE timestamp shows 07 Aug at 04:01 PM alongside “Article Data: 882.10”, and another line states the current share price is ₹882.85. Since these figures are presented as separate snapshots, they indicate that the stock was being tracked across different points in time and data feeds.

Q1 FY27 estimates cited: revenue and PAT ranges

The provided material includes an estimates table for Q1 FY27, with revenue expected in the ₹234-₹269 crore range versus Q1 FY26 actual revenue of ₹215 crore. It also shows an estimated PAT range of ₹15-₹19 crore versus Q1 FY26 PAT of ₹18 crore.

The same section notes an “indicative” results date window of July-August 2026. It also lists a 12-month share price target range estimate of ₹953-₹1,064.

Latest reported quarter and FY26 profit references

Ahead of Q1 FY27, the material cites the most recent reported quarter (Q4 FY26) with revenue of ₹243 crore and net profit of ₹16 crore as a base reference for the estimates framework.

It also provides reported consolidated quarterly numbers for March 2026: net sales of ₹238.50 crore (up 17.66% from ₹202.71 crore in March 2025), net profit of ₹15.99 crore (down 1.79% from ₹16.28 crore), and EBITDA of ₹29.64 crore (down 2.79% from ₹30.49 crore). EPS is stated at ₹7.58 for March 2026 versus ₹7.77 for March 2025.

For full-year profit, the material states: “Windlas Biotech FY26 Net Profit rises 9% to ₹66 crore” and separately lists profit of ₹66.46 crore for March 2026, ₹60.99 crore for March 2025 and ₹58.19 crore for March 2024.

Shareholding trend: promoter stake movement through Jun 2026

A shareholding table in the provided content shows promoters at 62.34% (Jun 2025), 61.99% (Sep 2025), 61.99% (Dec 2025), 61.90% (Mar 2026), and 63.31% (Jun 2026). It also lists “AKW WBL Family Private…” at 39.99% (Jun 2025) rising to 40.61% (Jun 2026), and “Ashok Kumar Windlass” at 20.99% (Jun 2025) rising to 21.32% (Jun 2026). Another line shows “Vimla Windlasss” at 1.35% (Dec 2025 and Mar 2026) and 1.38% (Jun 2026).

Corporate actions and calendar items mentioned

The material references a share buyback approval: “Windlas Biotech approves buyback of shares worth up to 470 million rupees,” which equals ₹47 crore. It also lists past result-related items, including “Windlas Biotech Dec-Quarter Consol Net Profit 150 million rupees,” which equals ₹15 crore.

An events list includes an upcoming quarterly results announcement date of Aug 10, 2026. It also mentions a dividend of ₹6.3 per share with an ex-date of Jul 16, 2026, and an annual report announcement date of Jul 01, 2026. Prior quarterly result dates listed include May 21, 2026; Feb 05, 2026; Nov 06, 2025; Aug 12, 2025, plus a dividend of ₹5.8 per share with an ex-date of Jul 21, 2025.

Why the call matters for investors and analysts

With Q1 FY27 numbers pending, the Aug 11 call creates a defined forum for management commentary on the quarter ended June 30, 2026. For investors, the immediate focus is likely to be on how reported revenue and profitability compare with the cited estimate ranges of ₹234-₹269 crore revenue and ₹15-₹19 crore PAT.

The disclosures also place Windlas Biotech’s operating context in view, including the three-vertical structure (CDMO, trade generics and institutional, exports). The material additionally states that as of “H1FY6”, about 74% of revenue came from CDMO, 22% from trade generics, and 4% from exports.

Conclusion

Windlas Biotech’s Q1 FY27 earnings call on August 11, 2026 at 11:30 AM IST sets the schedule for investor engagement around the quarter ended June 30, 2026. Alongside the call details, the provided information highlights promoter holding changes through June 2026, recent quarterly performance indicators, and an estimate range for Q1 FY27 revenue and PAT. The next key milestone flagged in the material is the quarterly results announcement date listed as Aug 10, 2026, followed by the management discussion on the conference call.